Artal Group’s Corvus Pharmaceuticals CRVS Stock Holding History

Artal Group’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-500,000	Closed	-$1.15M	–	108
2023 Q2	$1.15M	Hold	500,000	–	–	0.04%	90
2023 Q1	$455K	Hold	500,000	–	–	0.03%	105
2022 Q4	$425K	Hold	500,000	–	–	0.02%	116
2022 Q3	$409K	Hold	500,000	–	–	0.02%	126
2022 Q2	$495K	Hold	500,000	–	–	0.03%	123
2022 Q1	$820K	Hold	500,000	–	–	0.03%	129
2021 Q4	$1.21M	Hold	500,000	–	–	0.03%	137
2021 Q3	$2.42M	Buy	+500,000	New	+$1.48M	0.05%	131

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TowerView LLC New York $152M AUM 20.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Artal Group's CRVS Position: Q3 2023 in Review

Artal Group sold out of Corvus Pharmaceuticals (CRVS) in Q3 2023, closing a stake of 500,000 shares — an estimated $1.15M sold.

Artal Group first reported a position in CRVS in Q3 2021 and held it in 8 quarters. The position peaked at $2.42M in Q3 2021. 52 funds tracked by Wall St. Rank hold CRVS as of Q3 2023.

Artal Group reported no remaining Corvus Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Artal Group sold 500,000 Corvus Pharmaceuticals shares in Q3 2023, an estimated $1.15M.
Artal Group first reported a position in Corvus Pharmaceuticals in Q3 2021 and held it in 8 quarters.
Artal Group's Corvus Pharmaceuticals position peaked at $2.42M in Q3 2021.
52 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2023.

Based on Artal Group's 13F filing for Q3 2023, filed 13 Nov 2023.